Aurinia Pharmaceuticals Inc (AUPH) - Total Assets
Based on the latest financial reports, Aurinia Pharmaceuticals Inc (AUPH) holds total assets worth $792.26 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Aurinia Pharmaceuticals Inc - Total Assets Trend (1998–2025)
This chart illustrates how Aurinia Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data. Also see Aurinia Pharmaceuticals Inc stock valuation for the company's overall valuation and market capitalisation.
Aurinia Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Aurinia Pharmaceuticals Inc's total assets of $792.26 Million consist of 65.5% current assets and 34.5% non-current assets. Review Aurinia Pharmaceuticals Inc debt and liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 10.7% |
| Accounts Receivable | $41.45 Million | 5.5% |
| Inventory | $45.69 Million | 6.1% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $3.76 Million | 0.5% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1998–2025)
This chart illustrates how Aurinia Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See AUPH live share price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Aurinia Pharmaceuticals Inc's current assets represent 65.5% of total assets in 2025, an increase from 37.5% in 1998.
- Cash Position: Cash and equivalents constituted 10.7% of total assets in 2025, up from 0.0% in 1998.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 25.0% in 1998.
- Asset Diversification: The largest asset category is inventory at 6.1% of total assets.
Aurinia Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Aurinia Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
Aurinia Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.42 | 5.23 | 8.77 |
| Quick Ratio | 4.97 | 4.63 | 8.26 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $441.43 Million | $330.70 Million | $291.68 Million |
Aurinia Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Aurinia Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.43 |
| Latest Market Cap to Assets Ratio | 2.74 |
| Asset Growth Rate (YoY) | 36.5% |
| Total Assets | $751.59 Million |
| Market Capitalization | $2.06 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Aurinia Pharmaceuticals Inc's assets at a significant premium (2.74x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Aurinia Pharmaceuticals Inc's assets grew by 36.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Aurinia Pharmaceuticals Inc (1998–2025)
The table below shows the annual total assets of Aurinia Pharmaceuticals Inc from 1998 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $751.59 Million | +36.49% |
| 2024-12-31 | $550.64 Million | +0.47% |
| 2023-12-31 | $548.06 Million | +16.40% |
| 2022-12-31 | $470.86 Million | -13.34% |
| 2021-12-31 | $543.37 Million | +17.19% |
| 2020-12-31 | $463.66 Million | +42.97% |
| 2019-12-31 | $324.30 Million | +122.33% |
| 2018-12-31 | $145.86 Million | -23.17% |
| 2017-12-31 | $189.85 Million | +233.08% |
| 2016-12-31 | $57.00 Million | +69.80% |
| 2015-12-31 | $33.57 Million | -35.91% |
| 2014-12-31 | $52.38 Million | +126.33% |
| 2013-12-31 | $23.14 Million | +456.37% |
| 2012-12-31 | $4.16 Million | -70.96% |
| 2011-12-31 | $14.32 Million | +39.28% |
| 2010-12-31 | $10.28 Million | +7.70% |
| 2009-12-31 | $9.55 Million | -64.19% |
| 2008-12-31 | $26.66 Million | -37.52% |
| 2007-12-31 | $42.67 Million | +39.27% |
| 2006-12-31 | $30.64 Million | -43.63% |
| 2005-12-31 | $54.35 Million | -11.15% |
| 2004-12-31 | $61.17 Million | -17.82% |
| 2003-12-31 | $74.43 Million | +46.87% |
| 2002-12-31 | $50.68 Million | +36.74% |
| 2001-12-31 | $37.06 Million | +165.34% |
| 2000-12-31 | $13.97 Million | +237.19% |
| 1999-12-31 | $4.14 Million | +165.12% |
| 1998-12-31 | $1.56 Million | -- |
About Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and … Read more